By prolonging the anti retroviral therapy (with a regime containing a Reverse Transcriptase or Ingetrase Inhibitor) for a certain time after the CRISPR-Cas treatment should lead to the complete elimination of the viral DNA, comparable to PrEP in un-infected individuals.
By prolonging the anti retroviral therapy (with a regime containing a Reverse Transcriptase or Ingetrase Inhibitor) for a certain time after the CRISPR-Cas treatment should lead to the complete elimination of the viral DNA, comparable to PrEP in un-infected individuals.